OMB APPROVAL
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549			OMB Number: 3235-0058
						Expires: February 28, 2022
						Estimated average burden hours per response: 2.50
						SEC FILE NUMBER
			001-35756
			CUSIP NUMBER
			64049M209

 FORM 12b-25

NOTIFICATION OF LATE FILING

 

(Check One)						☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒  Form 10-Q ☐  Form 10-D    ☐  Form N-CEN    ☐  Form N-CSR
						For Period Ended: September 30, 2019
						☐  Transition Report on Form 10-K
						☐  Transition Report on Form 20-F
						☐  Transition Report on Form 11-K
						☐  Transition Report on Form 10-Q
			For the Transition Period Ended:

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: 

PART I — REGISTRANT INFORMATION

NEOGENOMICS, INC.

(Full Name of Registrant)

N/A

(Former Name if Applicable)

12701 Commonwealth Drive, Suite 9

(Address of Principal Executive Office (Street and Number))

Fort Myers, FL 33913

(City, State and Zip Code)

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

			(a)						The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒			(b)						The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
			(c)						The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Registrant is unable to file, without unreasonable effort and expense, its Form 10-Q Quarterly Report for the quarter ended September 30, 2019 as a result of extended review procedures in connection with the presentation of its Series A Redeemable Convertible Preferred Stock within its Consolidated Statements of Redeemable Preferred Stock and Stockholders’ Equity and Consolidated Balance Sheet. The Registrant notes that the Preferred Stock was fully redeemed in June 2018 and does not anticipate any changes to the total presentation of stockholders’ equity as a result of the extended review procedures. It is anticipated that the Form 10-Q Quarterly Report, along with the interim financial statements, will be filed on or before the 5th calendar day following the prescribed due date of the Registrant’s Form 10-Q.

PART IV — OTHER INFORMATION

(1)			Name and telephone number of person to contact in regard to this notification

Kathryn B. McKenzie

239

768-0600

(Name)

(Area Code)

(Telephone Number)

 

(2)			Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).    ☒  Yes    ☐  No
(3)			Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion hereof?    ☐  Yes    ☒  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made

NEOGENOMICS, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date

November 13, 2019

By

/s/ Douglas M. VanOort

Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

---

ATTENTION Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).